In the last few years, V-domain Ig-containing suppressor of T cell activation(VISTA) has been reported as a prognostic biomarker in articles including various solid tumours. However, their conclusions have been controversial. For this reason, we performed this meta-analysis to further verify the prognostic value of VISTA in solid tumours. All relevant literature was identified from PubMed, Embase, the Cochrane Library and Web of Science. Ten studies, including 2, 440 patients, were eligible for the analysis. The pooled results showed that high expression of VISTA was associated with favourable overall survival (OS) than that seen with low expression of VISTA (7 studies, hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.66-0.86, P < 0.001). In addition, high expression of VISTA significantly correlated with high numbers of CD8 (+) tumour infiltrating lymphocytes (TILs) (3 studies, risk ratio (RR) = 1.80, 95% CI: 1.41-2.31, P < 0.001). In conclusion, these results indicate that VISTA is a potential prognostic biomarker in solid tumours.
NSCLC, ovarian cancer (OC), primary cutaneous melanoma(PCM), gastric cancer(GC), EAC and malignant pleural mesothelioma(MPM). The sample size of the included studies ranged from 65 to 464. The expression level of VISTA in included studies is presented in Supplementary Table 2 . Among the 10 studies, 7 studies explored the prognostic value of VISTA in terms of patients' OS, 2 studies explored the TSS, and 1 study explored the DSS. As far as we understand, the data regarding TSS and DSS can be combined into one group.
Methodological quality of the included studies. The quality of the included studies was generally high.
All of the studies had an independent assessment of outcome. The majority of the included studies had long enough follow-up durations (5 years) , and most of them provided an adequate follow-up. However, none of these eligible studies had representativeness of the exposed cohort because the study objects were patients selected from the hospital. In the majority of the studies, methods for handling intention-to-treat analysis and missing data were not described adequately.
High expression of VISTA in solid tumours is associated with favourable OS. Seven studies 6, 7, [11] [12] [13] reported the relationship between the expression of VISTA and patients' OS. We applied a fixed effect model to calculate the pooled hazard ratio (HR) and 95% confidence interval (CI) because there was no obvious heterogeneity (P = 0.564, I 2 = 0.0%). The results showed that high expression of VISTA was associated with better OS than low expression of VISTA. (HR = 0.75, 95% CI: 0.66-0.86, P < 0.001, Fig. 2a ). [8] [9] [10] reported the relationship between the expression of VISTA and patients' DSS (or TSS). A random effect model was applied to calculate the pooled HR and 95% CI due to obvious heterogeneity (P = 0.003, I 2 = 82.6%). However, no obvious trend in DSS (or TSS) was found according to the expression of VISTA (HR = 1.57, 95% CI: 0.71-3.48, P = 0.268, Fig. 2b ).
The prognostic value of VISTA in patients' DSS(or TSS). Three studies

High expression of VISTA correlates with high numbers of CD8 (+) TILs.
To further analyse the possible factors that may affect the prognostic value of VISTA in solid tumours, we researched the correlation between the expression of VISTA and patients' clinicopathological characteristics. Interestingly, we found that high expression of VISTA was significantly associated with high numbers of CD8 (+) TILs (risk ratio (RR) = 1.80, 95% CI: 1.41-2.31, P < 0.001, Fig. 3 ). As shown in Table 2 , no obvious trend in TNM stage or gender was found according to the expression of VISTA. www.nature.com/scientificreports www.nature.com/scientificreports/ Sensitivity analysis and publication bias. Studies with high NOS scores (≥7) were included in the sensitivity analysis of the association between the expression of VISTA and patients' OS. As shown in Fig. 4 , there was no change in the trend regarding HR and 95% CI. High expression of VISTA correlated with a better OS than low expression of VISTA in the high NOS scores studies. According to the guideline, publication bias should not be assessed when the included studies are less than 10, so we did not evaluate the publication bias.
Discussion
As far as we know, this is the first study to systematically evaluate the prognostic value of VISTA in human solid tumours. Our results revealed that high expression of VISTA was associated with better OS. To further analyse the possible factors that may affect the prognostic value of VISTA in solid tumours, we investigated the correlation between the expression of VISTA and patients' clinicopathological characteristics. The results indicated that high expression of VISTA significantly correlated with high numbers of CD8 ( + ) TILs.
In the last few years, a number of molecules, such as PD-L1, programmed death 1(PD-1), lymphocyte activation gene 3(LAG3) and T cell immunoglobulin-and mucin-domain-containing molecule-3(TIM3) have been considered as negative immune checkpoints. In 2014, Lines 2 first defined VISTA as a new negative immune checkpoint. In vitro proliferation assays, VISTA suppressed the proliferation of both CD4 + and CD8 + T cells. In mouse models, VISTA blockade decelerated tumour growth, and overexpression of VISTA accelerated tumour growth. As described above, it seemed that VISTA was associated with poor prognosis. However, Villarroel 6 found that high levels of VISTA correlated with better OS in NSCLC. Coincidentally, Loeser's study 6 showed the same trend in esophageal adenocarcinoma. Moreover, we found the same trends not only in the studies of VISTA, but also in some studies of other negative immune molecules, such as PD-1 and PD-L1 [15] [16] [17] [18] [19] [20] . Badoua showed that PD-1 + TILs were associated with favourable OS in human papillomavirus(+) head and neck cancer. Similarly, Zhu's study demonstrated that high expression of PD-L1 on tumour cells correlated with better OS than that seen in nasopharyngeal carcinoma patients with low expression of PD-L1. The reasons that may account for this discrepancy include biological differences between mice and humans, different types of tumours and the subjective evaluation of immunohistochemistry (IHC) or immunofluorescence (IF) scores.
Recently, an increasing number of researchers [21] [22] [23] [24] [25] [26] [27] [28] [29] have paid great attention to the CD8 (+) TILs in the tumour microenvironment due to their anti-tumour effect. Gabrielson's research 21 illustrated that high numbers of CD8 (+) TILs significantly correlated with a low rate of recurrence and prolonged relapse-free survival in patients with HCC. Goode 22 showed that in high-grade serous ovarian cancer, high numbers of CD8 (+) TILs were significantly associated with improved OS. Ye 28 found that high numbers of CD8 (+) TILs predicted favourable prognosis in lung adenocarcinoma patients. These studies may indicate that CD8 (+) TILs are a prognostic biomarker that correlates with a favourable prognosis in solid tumours. In our study, we found that high expression of VISTA was remarkably associated with high numbers of CD8 (+) TILs. This result may partly account for the conclusion that high expression of VISTA correlates with favourable OS in solid tumours.
In conclusion, VISTA may act as a positive prognostic biomarker in solid tumours. Nevertheless, due to the current rarity of studies of the association between the expression of VISTA and patients' prognosis in solid tumours, we cannot assess publication bias. Therefore, more studies are required for further analysis.
Methods
Literature search strategy. We searched all relevant literature in Embase, PubMed, the Cochrane Library and Web of Science on September 28 th , 2019, without language restriction. These databases were thoroughly searched by the following strategy: ( Exclusion criteria. The exclusion criteria included the following: (1) the articles were conference abstracts or reviews; (2) full text of the article was not available; (3) the studies used animal models.
Data extraction and quality assessment. www.nature.com/scientificreports www.nature.com/scientificreports/ the NOS(scores: 0-9), and we defined studies that had high NOS scores (≥7) as high-quality. The investigators reached an agreement by mutual discussing when there were inconsistent results.
Statistical analysis. The association between the expression of VISTA and patients' prognosis was evaluated
by meta-analysis by collecting data from all included studies. We calculated outcome endpoints including OS, DSS and TSS via pooled HRs and 95% CIs. HRs > 1 indicated a poor prognosis. The correlation between the expression of VISTA and the clinicopathological characteristics was evaluated by pooled RRs and 95% CIs. Cochrane's Q statistic and the I 2 statistic were used to assess the heterogeneity among the included studies. A random effects model was used to calculate pooled HRs and 95% CIs when there was substantial heterogeneity (Q test: P < 0.1 or an I 2 > 50%). 
